EBSA conference 2023 evaluation EBSA conference 2023 evaluation General organisation, location, conference office12345 General evaluation Poor 1 - 2 - 3 - 4 - 5 Excellent Comments, remarks, questions, complaints, ... ? All feedback is welcome Session 1 Outbreak responseFrom laboratory containment and beyond - the role of biosafety and biosecurity during outbreaksÅsa Szekely Björndal, Public Health Agency, Sweden12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent 12345 Speaker (knowlegde, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Public Health Communication in a Crisis. The covid-19 experienceAlkiviadis Vatopoulos, National Public Health Organisation, Greece12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Mpox and the environment: implications for infection controlAllan Bennett OBE, UK Health Security Agency, United Kingdom12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments on session 1? Session 2 Biosafety Accelerator PitchThe poster presentations were already rates during the poster prize. Any extra comments or remarks on session 2 ? Company presentationsEnergy Recovery for Batch Thermal Effluent Decontamination SystemsGary Schmidt, PRI-Bio12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent 12345 Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Realising the Full Capacity and Capability of your Laboratory: Global Lessons Learned Tim Burke, Merrick12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on company presentations ? Chris Collins lectureBiological risks old and new: ancient viruses to SARS-CoV-2Jean-Michel Claverie, Professor (emeritus) at the School of Medicine of Aix-Marseille University, France12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on the Chris Collins lecture? Session 3 BioRisk Management of Athropod activitiesHandling arthropods under biosafety containment and associated risksEva Veronesi, University of Applied Sciences of Southern Switzerland Switzerland12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Handling ticks and tick-host studies in high-containment labsAysen Gargili Keles, Marmara University, Health Sciences Faculty,Turkey12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Vector-borne pathogen control in laboratory and field settings - Practical issues and approachesMarcel van Bergen, Radboud University and Medical Centre, Nijmegen, The Netherlands12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on session 3 ? Session 4 Biodiversity - one word diverse impactThe International Expert Group of Biosafety and Biosecurity Regulators (IEGBBR)Thomas Binz, Swiss Federal Office of Public Health, Switzerland12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent How to strengthen laboratory biosecurity within your organization: The importance of biosecurity awarenessMirjam Schaap, RIUVM, The Netherlands12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Biosecurity in animal production to improve animal health and reduce antimicrobial useJeroen Dewulf, Faculty of Veterinary Medicine, Ghent University, Belgium12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on session 4 ? Break outs Whick break-outs did you attend? Break-out 1 Biocides product regulation – challenges in biosafety Break-out 2 Emerging Diseases in EasternEurope/mediterranean region Break-out 3 New genomic Techniques Break-out 4 Decontamination and reuse of PPE Break-out 5 BioRisk challenges in relation to contained activities on Prion (like) Diseases Break-out 6 Human factors. "Local rationality" and the difference between intentional and unintentional human failures 12345 Break out 1 Biocides product regulation – challenges in biosafety Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 1 ? 12345 Break out 2 Emerging Diseases in EasternEurope/mediterranean region Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 2 ? 12345 Break out 3 New genomic Techniques Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 3 ? 12345 Break out 4 Decontamination and reuse of PPE Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 4 ? 12345 Break out 5 BioRisk challenges in relation to contained activities on Prion (like) Diseases Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 5 ? 12345 break out 6 Human factors. "Local rationality" and the difference between intentional and unintentional human failures Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 6 ? Session 5 Evidence-based Biorisk ManagementEvidence-based risk analyses for Maximum Containment LaboratoriesAndreas Kurth, Robert Koch Institute, Germany12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Showering-out in polio essential facilities: from requirement to evidence-based considerationPatrick Rüdelsheim, Perseus, Belgium12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent BioSafetyCabinets mythbusters: Does heat really affect my protection?Kara Held, The Baker Company, United States12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Empirical Studies in BiosafetyKelly Kim, Gryphon Scientific LLC, United States12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Contact details Your name (optional) Send
EBSA conference 2023 evaluation General organisation, location, conference office12345 General evaluation Poor 1 - 2 - 3 - 4 - 5 Excellent Comments, remarks, questions, complaints, ... ? All feedback is welcome Session 1 Outbreak responseFrom laboratory containment and beyond - the role of biosafety and biosecurity during outbreaksÅsa Szekely Björndal, Public Health Agency, Sweden12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent 12345 Speaker (knowlegde, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Public Health Communication in a Crisis. The covid-19 experienceAlkiviadis Vatopoulos, National Public Health Organisation, Greece12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Mpox and the environment: implications for infection controlAllan Bennett OBE, UK Health Security Agency, United Kingdom12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments on session 1? Session 2 Biosafety Accelerator PitchThe poster presentations were already rates during the poster prize. Any extra comments or remarks on session 2 ? Company presentationsEnergy Recovery for Batch Thermal Effluent Decontamination SystemsGary Schmidt, PRI-Bio12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent 12345 Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Realising the Full Capacity and Capability of your Laboratory: Global Lessons Learned Tim Burke, Merrick12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on company presentations ? Chris Collins lectureBiological risks old and new: ancient viruses to SARS-CoV-2Jean-Michel Claverie, Professor (emeritus) at the School of Medicine of Aix-Marseille University, France12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on the Chris Collins lecture? Session 3 BioRisk Management of Athropod activitiesHandling arthropods under biosafety containment and associated risksEva Veronesi, University of Applied Sciences of Southern Switzerland Switzerland12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Handling ticks and tick-host studies in high-containment labsAysen Gargili Keles, Marmara University, Health Sciences Faculty,Turkey12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Vector-borne pathogen control in laboratory and field settings - Practical issues and approachesMarcel van Bergen, Radboud University and Medical Centre, Nijmegen, The Netherlands12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on session 3 ? Session 4 Biodiversity - one word diverse impactThe International Expert Group of Biosafety and Biosecurity Regulators (IEGBBR)Thomas Binz, Swiss Federal Office of Public Health, Switzerland12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent How to strengthen laboratory biosecurity within your organization: The importance of biosecurity awarenessMirjam Schaap, RIUVM, The Netherlands12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Biosecurity in animal production to improve animal health and reduce antimicrobial useJeroen Dewulf, Faculty of Veterinary Medicine, Ghent University, Belgium12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Any extra comments or remarks on session 4 ? Break outs Whick break-outs did you attend? Break-out 1 Biocides product regulation – challenges in biosafety Break-out 2 Emerging Diseases in EasternEurope/mediterranean region Break-out 3 New genomic Techniques Break-out 4 Decontamination and reuse of PPE Break-out 5 BioRisk challenges in relation to contained activities on Prion (like) Diseases Break-out 6 Human factors. "Local rationality" and the difference between intentional and unintentional human failures 12345 Break out 1 Biocides product regulation – challenges in biosafety Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 1 ? 12345 Break out 2 Emerging Diseases in EasternEurope/mediterranean region Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 2 ? 12345 Break out 3 New genomic Techniques Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 3 ? 12345 Break out 4 Decontamination and reuse of PPE Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 4 ? 12345 Break out 5 BioRisk challenges in relation to contained activities on Prion (like) Diseases Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 5 ? 12345 break out 6 Human factors. "Local rationality" and the difference between intentional and unintentional human failures Content (Poor 1 - 2 - 3 - 4 - 5 Excellent) Any extra comments or remarks on Break-out 6 ? Session 5 Evidence-based Biorisk ManagementEvidence-based risk analyses for Maximum Containment LaboratoriesAndreas Kurth, Robert Koch Institute, Germany12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Showering-out in polio essential facilities: from requirement to evidence-based considerationPatrick Rüdelsheim, Perseus, Belgium12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent BioSafetyCabinets mythbusters: Does heat really affect my protection?Kara Held, The Baker Company, United States12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Empirical Studies in BiosafetyKelly Kim, Gryphon Scientific LLC, United States12345 Content Poor 1 - 2 - 3 - 4 - 5 Excellent Speaker (knowledge, language, QA, ...) Poor 1 - 2 - 3 - 4 - 5 Excellent Contact details Your name (optional) Send
